5.90
+0(+0.00%)
Currency In USD
| Previous Close | 5.9 |
| Open | 5.83 |
| Day High | 6.07 |
| Day Low | 5.83 |
| 52-Week High | 7.37 |
| 52-Week Low | 2.41 |
| Volume | 278,718 |
| Average Volume | 1.1M |
| Market Cap | 459.66M |
| PE | -2.38 |
| EPS | -2.48 |
| Moving Average 50 Days | 5.3 |
| Moving Average 200 Days | 4.92 |
| Change | 0 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $17.39 as of December 25, 2025 at a share price of $5.9. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $59.24 as of December 25, 2025 at a share price of $5.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
GlobeNewswire Inc.
Dec 16, 2025 9:51 PM GMT
CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it w
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLEST